Experienced in Periventricular Leukomalacia

Dr. Myra H. Wyckoff

Neonatology | Pediatrics
5323 Harry Hines Blvd, 
Dallas, TX 
Experienced in Periventricular Leukomalacia
5323 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Myra Wyckoff is a Neonatologist and a Pediatrics provider in Dallas, Texas. Dr. Wyckoff is rated as an Experienced provider by MediFind in the treatment of Periventricular Leukomalacia. Her top areas of expertise are Premature Infant, Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, and Hypothermia.

Her clinical research consists of co-authoring 155 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Periventricular Leukomalacia.

Specialties
Neonatology
Pediatrics
Licenses
Pediatrics in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

5323 Harry Hines Blvd, Dallas, TX 75390

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Management of the Patent Ductus Arteriosus in Premature Infants Trial (PDA Trial)
Management of the Patent Ductus Arteriosus in Premature Infants Trial (PDA Trial)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other
Study Phase: Phase 3
Randomized Controlled Trial of Budesonide + Surfactant Versus Surfactant Alone in Extremely Preterm Infants (The Budesonide in Babies (BiB) Trial)
Randomized Controlled Trial of Budesonide + Surfactant Versus Surfactant Alone in Extremely Preterm Infants (The Budesonide in Babies (BiB) Trial)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: Budesonide (Pulmicort Nebulizing Suspension), Surfactant (Poractant Alfa
Study Phase: Phase 3
A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age
A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Drug
Study Drug: Hydrocortisone
Study Phase: Phase 3
A Randomized Trial of Targeted Temperature Management With Whole Body Hypothermia For Moderate And Severe Hypoxic-Ischemic Encephalopathy In Premature Infants 33-35 Weeks Gestational Age.
A Randomized Trial of Targeted Temperature Management With Whole Body Hypothermia For Moderate And Severe Hypoxic-Ischemic Encephalopathy In Premature Infants 33-35 Weeks Gestational Age.
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Device, Procedure
Study Phase: Not Applicable
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Enrollment Status: Completed
Publish Date: July 18, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?
Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?
Enrollment Status: Active_not_recruiting
Publish Date: March 22, 2024
Intervention Type: Procedure
Study Phase: Phase 3
Neurodevelopmental Effects of Donor Human Milk vs. Preterm Formula in Extremely Low Birth Weight (ELBW) Infants
Neurodevelopmental Effects of Donor Human Milk vs. Preterm Formula in Extremely Low Birth Weight (ELBW) Infants
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Biological, Dietary supplement
Study Drug: Donor Breast Milk
Study Phase: Phase 3
Early-Onset Sepsis an NICHD/CDC Surveillance Study
Early-Onset Sepsis an NICHD/CDC Surveillance Study
Enrollment Status: Completed
Publish Date: March 11, 2019
View 8 Less Clinical Trials

154 Total Publications

Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.
Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.
Journal: JAMA
Published: September 30, 2025
Similar Doctors
Distinguished in Periventricular Leukomalacia
Dr. Daniel J. Licht
Pediatric Neurology | Pediatrics | Neurology
Distinguished in Periventricular Leukomalacia
Dr. Daniel J. Licht
Pediatric Neurology | Pediatrics | Neurology
Dallas, TX 
 (2.8 miles away)
Languages Spoken:
English
See accepted insurances

Daniel Licht is a Pediatric Neurologist and a Pediatrics provider in Dallas, Texas. Dr. Licht is rated as a Distinguished provider by MediFind in the treatment of Periventricular Leukomalacia. His top areas of expertise are Periventricular Leukomalacia, Cerebral Hypoxia, Agyria Pachygyria Polymicrogyria, PHACE Syndrome, and Thrombectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wyckoff's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile